Acute Myeloid Leukemia

News Acute Myeloid Leukemia

• Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS

  Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with more

• New research shows promise killing leukemia cells

  Ben-Gurion University of the Negev’s Prof. Ilana Nathan and her team are interested in cell death. Specifically, they investigate all sorts of chemical compounds that can kill leukemia cancer cells by taking a ‘WISE’ investigational approach. What’s unique about the research is that she and her team more

• Elacytarabine in combination with idarubicin shows promising efficacy in Phase II trial in acute myeloid leukaemia

  Clavis Pharma ASA announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed.  The results found that treatment with more

White papers Acute Myeloid Leukemia

• Acquired Copy Number Alterations in Adult Acute Myeloid Leukemia Genomes
  

  To complement cytogenetic studies and to identify genes altered in AML genomes, Walter and co-workers performed a genome-wide copy number analysis with paired normal and tumor DNA obtained from 86 adult subjects with de novo AML using 1.85 million feature SNP arrays. A total of 201 somatic CNAs were found in the 86 AML genomes (mean, 2.34 CNAs per genome), with FAB-System M6 and M7 genomes containing the most changes (10-29 CNAs per genome). According to the authors' conclusions, the use of an unbiased high-resolution genomic screen identified many genes not previously implicated in AML that may be relevant for pathogenesis, along with many known oncogenes and tumor suppressor genes. Despite the ability of next-generation sequencing platforms to accurately identify amplifications, deletions, and translocations, a multiplatform approach (traditional cytogenetics, FISH, SNP array, array CGH, and targeted gene resequencing) will continue to be the most practical approach to studying AML genomes at most institut more

Publications Acute Myeloid Leukemia

• NUP98‐NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia

  The cryptic t(5;11)(q35;p15.5) creates a fusion gene between the NUP98 and NSD1 genes. To ascertain the significance of this gene fusion, we explored its frequency, clinical impact, and gene expression pattern using DNA microarray in pediatric acute myeloid leukemia (AML) patients. NUP98‐NSD1 fusi more

• The NSD1 and EZH2 Overgrowth Genes, Similarities and Differences

  Abstract NSD1 and EZH2 are SET domain‐containing histone methyltransferases that play key roles in the regulation of transcription through histone modification and chromatin modeling: NSD1 preferentially methylates lysine residue 36 of histone 3 (H3K36) and is primarily associated with active t more

• Characterization of chromosome 11 breakpoints and the areas of deletion and amplification in patients with newly diagnosed acute myeloid leukemia

  Chromosome 11 abnormalities are found in many hematological malignancies. In acute myeloid leukemia (AML), a proto‐oncogene MLL (11q23.3) is frequently altered. However, rearrangements involving other regions of chromosome 11 have been reported. Therefore, we have characterized the chromosome 11 b more

Market studies Acute Myeloid Leukemia

• Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma

  GBI Research, the leading business intelligence provider, has released its latest research report, “Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma” providing an insight into different endpoints that are used in orphan disease clinical more

• Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage ...

  GBI Research, the leading business intelligence provider, has released its latest research “Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules”, which provides insi more

• Acute Myeloid Leukemia (AML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Acute Myeloid Leukemia (AML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global acute myeloid leukemia (AML) therapeut more

Websites Acute Myeloid Leukemia